Silence Therapeutics CEO Craig Tooman departs by mutual consent; Chairman Iain Ross named interim CEO

Silence Therapeutics plc

Craig Tooman stepped down as President, CEO and Board member effective Dec 14, 2025 by mutual consent.
Chairman Iain Ross appointed as interim principal executive officer effective immediately.
James Ede-Golightly re-appointed to Board; previously served as Non-Executive Director from 2019 to June 2025.
Company expects to add a US-based Board member in due course.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.